Investors in Advanced Micro Devices (NASDAQ:AMD) are accustomed to seeing shares make big moves. And usually the direction they move is up. Until last week, AMD stock had gained an impressive 388% over the past two years.Source: Joseph GTK / Shutterstock.com However, in the midst of marketwide panic over the coronavirus from China, AMD has been taking a serious beating. On Monday, it dropped 7.8% -- more than double the losses for the NASDAQ as a whole, which closed 3.7% lower on the day. Since closing at an all-time high of $58.90 last Wednesday, AMD has dropped 9.5%.The big drop, and the fact that AMD is being hit much harder than other tech stocks, is raising questions. The big one, of course, is will AMD recover from this selloff?InvestorPlace - Stock Market News, Stock Advice & Trading Tips Coronavirus Takes Its Toll on the Markets, Wallops AMDOn Monday, the markets appeared...
With shares down more than 80%, is there opportunity with Acasti Pharma (NASDAQ:ACST) stock? Don't bet on it! Shares have been hammered since January due to poor Phase 3 results for its prospective hypertriglyceridema treatment CaPre. Like with many biotech stocks, Acasti Pharma stock is a binary play on a single drug's success. Failure for CaPre is bad news for Acasti shares.Source: Pavel Kapysh / Shutterstock.com Considering this factor, there's good reason shares could fall further. Hemorrhaging cash, the company will likely need a dilutive equity infusion to stay in business. This would put further downward pressure on Acasti Pharma stock.Yet, I would not say Acasti Pharma stock has no shot at rebounding. If the company can press on with CaPre, shares could soar if subsequent trials prove successful. However, with Amarin's (NASDAQ:AMRN) competing treatment Vascepa moving ahead, CaPre could easily wind up left in the dust.InvestorPlace - Stock Market News,...